Adalimumab, azathioprine or mesalazine for the prevention of postoperative recurrence of Crohn's disease

Trial Profile

Adalimumab, azathioprine or mesalazine for the prevention of postoperative recurrence of Crohn's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Adalimumab (Primary) ; Azathioprine; Mesalazine
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jun 2013 New trial record
    • 18 May 2013 Primary endpoint 'Disease-recurrence-rate' has been met.
    • 18 May 2013 Results presented at the Digestive Disease Week 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top